{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["EGFR mutation", "afatinib", "non-small-cell lung cancer", "osimertinib", "real world data"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "33984681", "DateCompleted": {"Year": "2021", "Month": "10", "Day": "29"}, "DateRevised": {"Year": "2022", "Month": "06", "Day": "03"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2021", "Month": "05", "Day": "10"}], "ELocationID": ["100115", "10.1016/j.esmoop.2021.100115", "S2059-7029(21)00073-9"], "Journal": {"ISSN": "2059-7029", "JournalIssue": {"Volume": "6", "Issue": "3", "PubDate": {"Year": "2021", "Month": "Jun"}}, "Title": "ESMO open", "ISOAbbreviation": "ESMO Open"}, "ArticleTitle": "A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903.", "Pagination": {"StartPage": "100115", "MedlinePgn": "100115"}, "Abstract": {"AbstractText": ["FLAURA, the prospective trial of osimertinib as a first-line therapy compared with first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), did not show superior survival benefit for osimertinib in either the subgroup of Asians or the subgroup with the L858R mutation. In addition, the superiority of osimertinib compared with second-generation EGFR-TKI is thus far unclear.", "We reviewed the clinical data of all consecutive patients who were treated with osimertinib or afatinib as first-line therapy between May 2016 and October 2019 from 15 institutions in Japan. We defined the groups based on first-line EGFR-TKI as the afatinib group and the osimertinib group. Outcomes included time to discontinuation of any EGFR-TKI (TD-TKI), overall survival (OS), and time to treatment failure, with propensity score analysis carried out as an exploratory analysis in the survival and subgroup analyses.", "A total of 554 patients were enrolled. Data on 326 patients in the osimertinib group, and 224 patients in the afatinib group were analyzed. TD-TKI adjusted by propensity score in the afatinib and osimertinib groups was 18.6 months (95% confidence interval 15.8 to 22.0) and 20.5 months (95% confidence interval 13.8 to not reached), respectively, without significant difference (P\u00a0= 0.204). OS adjusted by propensity score favored the afatinib group with a significant difference (P\u00a0= 0.018). Subgroup analysis with propensity score showed that patients with L858R and without brain metastasis had superior survival benefit with afatinib compared with osimertinib (P < 0.001).", "TD-TKI in the afatinib group was not significantly prolonged compared with the osimertinib group in the practical data. In the exploratory analysis of patients with L858R-mutated non-small-cell lung cancer without brain metastasis, afatinib showed more benefit in OS over osimertinib."], "CopyrightInformation": "Copyright \u00a9 2021 The Authors. Published by Elsevier Ltd.. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan; Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan."}], "LastName": "Ito", "ForeName": "K", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan. Electronic address: morisem@med.nagoya-u.ac.jp."}], "LastName": "Morise", "ForeName": "M", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Thoracic Oncology, Shizuoka Cancer Center, Suntou-gun, Shizuoka, Japan."}], "LastName": "Wakuda", "ForeName": "K", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan."}], "LastName": "Hataji", "ForeName": "O", "Initials": "O"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan."}], "LastName": "Shimokawaji", "ForeName": "T", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Anjo Kosei Hospital, Anjo, Aichi, Japan."}], "LastName": "Takahashi", "ForeName": "K", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan."}], "LastName": "Furuya", "ForeName": "N", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan."}], "LastName": "Takeyama", "ForeName": "Y", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan."}], "LastName": "Goto", "ForeName": "Y", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Ogaki Municipal Hospital, Ogaki, Gifu, Japan."}], "LastName": "Abe", "ForeName": "T", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Respiratory Medicine and Allergology, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan."}], "LastName": "Kato", "ForeName": "T", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan."}], "LastName": "Ozone", "ForeName": "S", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan."}], "LastName": "Ikeda", "ForeName": "S", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan."}], "LastName": "Kogure", "ForeName": "Y", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Aichi, Japan."}], "LastName": "Yokoyama", "ForeName": "T", "Initials": "T"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Toyota Memorial Hospital, Toyota, Aichi, Japan."}], "LastName": "Kimura", "ForeName": "M", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Osaka, Japan."}], "LastName": "Yoshioka", "ForeName": "H", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biostatistics Center, Kurume University, Kurume, Fukuoka, Japan."}], "LastName": "Murotani", "ForeName": "K", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan."}], "LastName": "Kondo", "ForeName": "M", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Respiratory Medicine, Matsunami General Hospital, Kasamatsu, Gifu, Japan."}], "LastName": "Saka", "ForeName": "H", "Initials": "H"}], "PublicationTypeList": ["Journal Article", "Multicenter Study", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "ESMO Open", "NlmUniqueID": "101690685", "ISSNLinking": "2059-7029"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Acrylamides"}, {"RegistryNumber": "0", "NameOfSubstance": "Aniline Compounds"}, {"RegistryNumber": "3C06JJ0Z2O", "NameOfSubstance": "osimertinib"}, {"RegistryNumber": "41UD74L59M", "NameOfSubstance": "Afatinib"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Acrylamides"}, {"QualifierName": ["therapeutic use"], "DescriptorName": "Afatinib"}, {"QualifierName": [], "DescriptorName": "Aniline Compounds"}, {"QualifierName": [], "DescriptorName": "Antineoplastic Combined Chemotherapy Protocols"}, {"QualifierName": ["drug therapy", "genetics"], "DescriptorName": "Carcinoma, Non-Small-Cell Lung"}, {"QualifierName": [], "DescriptorName": "Cohort Studies"}, {"QualifierName": ["genetics"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "genetics"], "DescriptorName": "Lung Neoplasms"}, {"QualifierName": [], "DescriptorName": "Prospective Studies"}], "CoiStatement": "Disclosure KI reports personal fees from Boehringer Ingelheim, AstraZeneca, Pfizer, Eli Lilly, Chugai Pharmaceutical, Merk Sharp & Dohme (MSD), Ono Pharmaceutical, and Taiho Pharmaceutical. MM reports grants from Boehringer Ingelheim, Eli Lilly; personal fees from Eli Lilly, Chugai, Astra Zeneca, Ono, Pfizer, MSD; nonfinancial support from F. Hoffmann-La Roche; others from Chugai, Astra Zeneca, Pfizer, Merk Serono, Kissei, Taiho, and Novartis. KW reports grants from Chugai Pharmaceutical Co., Ltd, AstraZeneca, Novartis, and Abbie; receiving personal fees from Chugai Pharmaceutical Co., Ltd, Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly K.K., Ono Pharmaceutical, MSD, and AstraZeneca. OH reports grants from AstraZeneca, Novartis, Boehringer Ingelheim, Byer, Daiichi Sankyo, GlaxoSmithKline; personal fees from AstraZeneca, Novartis, and Boehringer Ingelheim. TS has patents pending with AstraZeneca, Bristol-Myers Squibb, Ono Pharmaceutical, and Takeda. KT reports personal fees from AstraZeneca, Boehringer Ingelheim, Chugai, Eli Lilly, MSD, Taiho, and Novartis. NF reports personal fees from Eli Lilly Japan, Chugai, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim Japan, Taiho, Ono, and Pfizer Japan. TK reports personal fees from Boehringer Ingelheim and AstraZeneca. SI reports grants from AstraZeneca and Chugai; personal fees from AstraZeneca, Boehringer Ingelheim, Ono, Taiho, Bristol Myers Squibb, Eli Lilly Japan, Pfizer, and Chugai. YK reports grants from MSD; personal fees from AstraZeneca, Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Taiho Pharmaceutical, and Eli Lilly. HY reports personal fees from Boehringer Ingelheim, AstraZeneca, Chugai pharmaceutical, Eli Lilly, Pfizer, Bristol-Myers Squibb, Ono Pharmaceutical, MSD KK, Novartis, Kyowa Hakko Kirin, Daiichi Sankyo, Delta-Fly Pharma, Nippon Kayaku, and Taiho Pharmaceutical. MK reports grants from Eli Lilly; receiving personal fees from Eli Lilly, CHUGAI PHARMACEUTICAL CO, AstraZeneca, MSD, ONO PHARMACEUTICAL CO, Bristol Myers Squibb, Takeda Pharmaceutical Company, and Boehringer Ingelheim. HS reports grants from AstraZeneca, MSD (Merk), Ono Pharmaceutical, Eli Lilly Japan, Chugai Pharmaceutical, Bristol Myers Squibb, Quintiles Transnational Japan, Chugai Pharmaceutical, Beyer Pharmaceuticals, Olympus, Boehringer Ingelheim Japan, West Japan Oncology Group, AC Medical, Novartis Pharma, Japan Blood Products Organization, CMIC HOLDINGS, Takeda, A2 Healthcare, Otsuka, Pfizer, Parexel International, Boston Scientific, Harada, Nobelpharma, Taisho Toyama Pham; personal fees from AstraZeneca, MSD (Merk), Ono Pharmaceutical, Eli Lilly Japan, Covidien Japan, Taiho Pharmaceutical, Becton, Dickinson and Company, AMCO Inc., Kyowa Hakko Kirin, KYORIN Pharmaceutical, Chugai Pharmaceutical, Olympus, Boehringer Ingelheim Japan, Novartis Pharma, Pfizer, Parexel International, and Boston Scientific. All other authors have declared no conflicts of interest. Role of the funder/sponsor The funding sources from CJLSG had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Jorissen R.N., Walker F., Pouliot N. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284:31\u201353.", "ArticleIdList": ["12648464"]}, {"Citation": "Maemondo M., Inoue A., Kobayashi K. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N\u00a0Engl J Med. 2010;362:2380\u20132388.", "ArticleIdList": ["20573926"]}, {"Citation": "Mok T.S., Wu Y.L., Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N\u00a0Engl J Med. 2009;361:947\u2013957.", "ArticleIdList": ["19692680"]}, {"Citation": "Rosell R., Carcereny E., Gervais R. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239\u2013246.", "ArticleIdList": ["22285168"]}, {"Citation": "Sequist L.V., Yang J.C., Yamamoto N. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J\u00a0Clin Oncol. 2013;31:3327\u20133334.", "ArticleIdList": ["23816960"]}, {"Citation": "Wu Y.L., Zhou C., Hu C.P. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213\u2013222.", "ArticleIdList": ["24439929"]}, {"Citation": "Wu Y.L., Zhou C., Liam C.K. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015;26:1883\u20131889.", "ArticleIdList": ["26105600"]}, {"Citation": "Soria J.C., Ohe Y., Vansteenkiste J. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N\u00a0Engl J Med. 2018;378:113\u2013125.", "ArticleIdList": ["29151359"]}, {"Citation": "Mok T.S., Wu Y.L., Ahn M.J. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N\u00a0Engl J Med. 2017;376:629\u2013640.", "ArticleIdList": ["PMC6762027", "27959700"]}, {"Citation": "Park K., Bennouna J., Boyer M. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2019;132:126\u2013131.", "ArticleIdList": ["31097085"]}, {"Citation": "Hochmair M.J., Morabito A., Hao D. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol. 2018;14:2861\u20132874.", "ArticleIdList": ["30336693"]}, {"Citation": "Hochmair M.J., Morabito A., Hao D. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol. 2019;15:2905\u20132914.", "ArticleIdList": ["31370698"]}, {"Citation": "Ramalingam S.S., Vansteenkiste J., Planchard D. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N\u00a0Engl J Med. 2020;382:41\u201350.", "ArticleIdList": ["31751012"]}, {"Citation": "Planchard D., Boyer M.J., Lee J.S. Postprogression outcomes for osimertinib versus standard-of-care EGFR-TKI in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer. Clin Cancer Res. 2019;25:2058\u20132063.", "ArticleIdList": ["30659024"]}, {"Citation": "Cho B.C., Chewaskulyong B., Lee K.H. Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset. J\u00a0Thorac Oncol. 2019;14:99\u2013106.", "ArticleIdList": ["30240852"]}, {"Citation": "Ballard P., Yates J.W., Yang Z. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22:5130\u20135140.", "ArticleIdList": ["27435396"]}, {"Citation": "Colclough N., Chen K., Johnstr\u00f6m P. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res. 2021;27:189\u2013201.", "ArticleIdList": ["33028591"]}, {"Citation": "Seto T., Nogami N., Yamamoto N. Real-world EGFR T790M testing in advanced non-small-cell lung cancer: a prospective observational study in Japan. Oncol Ther. 2018;6:203\u2013215.", "ArticleIdList": ["PMC7359964", "32700028"]}, {"Citation": "Nadler E., Pavilack M., Espirito J.L., Clark J., Fernandes A. Observational study of treatment patterns in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after first-line EGFR-tyrosine kinase inhibitors. Adv Ther. 2020;37:946\u2013954.", "ArticleIdList": ["31955357"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "11", "Day": "27"}, {"Year": "2021", "Month": "3", "Day": "14"}, {"Year": "2021", "Month": "3", "Day": "19"}, {"Year": "2021", "Month": "5", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "10", "Day": "30", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "5", "Day": "13", "Hour": "20", "Minute": "23"}, {"Year": "2021", "Month": "5", "Day": "10"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33984681", "PMC8134659", "10.1016/j.esmoop.2021.100115", "S2059-7029(21)00073-9"]}}], "PubmedBookArticle": []}